Drug Discovery & DDS– category –
-
UVA Health Breakthrough: Focused Ultrasound Breaches Blood-Brain Barrier for Glioma Treatment, Identifies Optimal Drug Size
UVA Health USA Overview Researchers at UVA Health discovered that gliomas are more receptive to targeted drug delivery via focused ultrasound than normal brain tissue. This technique uses microbubbles activated by sound waves to temporar... -
Low-Intensity Focused Ultrasound and Microbubbles Temporarily Open Blood-Brain Barrier, Unlocking Brain Drug Delivery
Drug Target Review UK Overview Researchers are investigating low-intensity focused ultrasound (LIFU) combined with intravenously administered microbubbles to temporarily and reversibly increase the permeability of the blood-brain barrier... -
Bispecific Antibody-Conjugated Lipid Nanoparticles Achieve Cell-Specific mRNA Delivery, Overcoming Liver Tropism
ACS Publications USA Overview Researchers have developed a bispecific antibody-conjugated lipid nanoparticle (TbsAb-LNP) platform designed for precise, cell-specific mRNA delivery, effectively circumventing the inherent liver tropism of ... -
Drug Discovery & DDS Weekly Report August 2, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report August 02, 2026 (PDF) — Download Weekly Report August 02, 2026 (PDF) — DownloadDownload 🎙 Podcast August 02, ... -
Ribo’s Divesiran (SLN124) Significantly Reduces Phlebotomy Frequency and Improves Patient QoL in Polycythemia Vera Phase IIa Trial
MPN Research Foundation Global Overview Divesiran (SLN124) from Ribo is an siRNA therapy designed to increase hepcidin levels, aiming to control erythrocyte overproduction in polycythemia vera (PV). Clinical trial results showed that pat... -
Heart-Specific LNP Delivery for Myocardial Infarction Remains a Challenge: Conventional LNPs Accumulate in Liver, while Novel Lipid Engineering Targets Lungs and Spleen
American Heart Association Journals USA Overview Lipid nanoparticles (LNPs) are clinically validated non-viral vectors for delivering therapeutics like small molecules, mRNA, and siRNA; however, achieving heart-specific drug delivery for... -
Molecular Glue Development Accelerates: Gluetacs and Degron Advance Key Programs in Targeted Protein Degradation
GlobeNewswire Global Overview The field of molecular glues, a powerful targeted protein degradation (TPD) modality, is rapidly expanding with two significant clinical advancements: Gluetacs Therapeutics has initiated a Phase II trial for... -
FDA Grants Accelerated Approval to Nuvalent’s Zidesamtinib (Jideytro) for ROS1-Positive NSCLC, Two Months Ahead of PDUFA Date
FDA USA Overview On July 22, 2026, the FDA approved Nuvalent, Inc.'s zidesamtinib (Jideytro) for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) previously treated with at least one ROS... -
Generative AI Forges Unprecedented Flavor Molecules, Reshaping the Food Industry
Industry Today USA Overview Generative AI has achieved a significant breakthrough in molecular biology, enabling the de novo design of entirely new flavor molecules that do not exist in nature. This sophisticated system analyzes vast che... -
Focused Ultrasound and Microbubbles Temporarily Open Blood-Brain Barrier for Enhanced Brain Drug Delivery
Drug Target Review UK Overview The blood-brain barrier (BBB) obstructs most therapeutic agents from reaching the brain, a major hurdle in treating neurological disorders. Researchers are advancing focused ultrasound (FUS), specifically l...
